BioMarin Pharmaceutical Inc. (BMRN) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 79.7% | 17.0% | 15.0% |
| 2023 | 78.0% | 7.7% | 6.9% |
| 2022 | 76.0% | 7.7% | 6.8% |
| 2021 | 74.5% | -4.5% | -3.5% |
Download Data
Export BMRN earnings history in CSV or JSON format
Free sign-in required to download data
BioMarin Pharmaceutical Inc. (BMRN) Earnings Overview
As of February 28, 2026, BioMarin Pharmaceutical Inc. (BMRN) reported trailing twelve-month net income of $349M, reflecting +11.9% year-over-year growth. The company earned $1.77 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, BMRN's 5-year EPS compound annual growth rate (CAGR) stands at -50.1%, signaling declining earnings. The company achieved its highest annual net income of $854M in fiscal 2020.
BioMarin Pharmaceutical Inc. maintains positive profitability with a gross margin of 0.8%, operating margin of 0.2%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), BMRN has outperformed on profitability metrics. Compare BMRN vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $27M | -93.7% | $0 | $0.14 | - | - |
| 2024 | $427M | +154.6% | $484M | $2.21 | 15.0% | 17.0% |
| 2023 | $168M | +18.4% | $186M | $0.88 | 6.9% | 7.7% |
| 2022 | $142M | +320.9% | $161M | $0.75 | 6.8% | 7.7% |
| 2021 | -$64M | -107.5% | -$82M | $-0.35 | -3.5% | -4.5% |
| 2020 | $854M | +3681.1% | -$43M | $4.53 | 45.9% | -2.3% |
| 2019 | -$24M | +69.1% | -$100M | $-0.13 | -1.4% | -5.9% |
| 2018 | -$77M | +34.0% | -$124M | $-0.44 | -5.2% | -8.3% |
| 2017 | -$117M | +81.4% | -$15M | $-0.67 | -8.9% | -1.1% |
| 2016 | -$630M | -266.8% | -$803M | $-3.79 | -56.4% | -71.9% |
See BMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BMRN vs AGIO
See how BMRN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BMRN growing earnings?
BMRN EPS stands at $1.77, with +11.9% growth matching the 5-year CAGR of -50.1%. TTM net income is $349M. Earnings trajectory remains consistent.
What are BMRN's profit margins?
BioMarin Pharmaceutical Inc. net margin is +0.1%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are BMRN's earnings?
BMRN earnings data spans 1998-2025. The current earnings trend is +11.9% YoY. Historical data enables comparison across business cycles.